Sudden Cardiac Death Prevention

📋 Key Information Summary

📋

Sudden cardiac death (SCD) accounts for approximately 20,000–30,000 deaths annually in Australia, representing a major public health burden disproportionately affecting Aboriginal and Torres Strait Islander communities.
Left ventricular ejection fraction (LVEF) ≤35% remains the single most important criterion for primary prevention implantable cardioverter-defibrillator (ICD) candidacy; measurement should be obtained ≥40 days post-MI and ≥3 months of optimal guideline-directed medical therapy (GDMT).
For ischaemic cardiomyopathy, the MUSTT and MADIT-II trial data support ICD implantation in patients with LVEF ≤35% and NYHA class II–III symptoms despite ≥3 months of GDMT; SCD-HeFT extended this to NYHA class III.
Non-ischaemic dilated cardiomyopathy (DCM) with LVEF ≤35% on GDMT qualifies for primary prevention ICD; however, DANISH trial data showed more modest absolute benefit compared with ischaemic aetiology, mandating shared decision-making.
Hypertrophic cardiomyopathy (HCM) risk stratification uses the ESC HCM Risk-SCD calculator incorporating septal thickness, left atrial size, LVOT gradient, family history of SCD, non-sustained VT, unexplained syncope, and late gadolinium enhancement on CMR.
Channelopathies (Long QT syndrome, Brugada syndrome, CPVT) require gene-specific and phenotype-specific risk stratification; β-blockers are first-line for LQTS and CPVT; quinidine or catheter ablation for Brugada with recurrent VF storms.
Secondary prevention ICD is indicated for survivors of cardiac arrest due to VT/VF (excluding reversible causes), and for patients with sustained VT in the setting of structural heart disease or significant LV dysfunction.
The wearable cardioverter defibrillator (WCD, LifeVest®) serves as a bridge to ICD during the 40-day post-MI window, during myocarditis recovery, and while awaiting LVEF reassessment after ≥3 months of GDMT optimisation.
All patients being considered for ICD must undergo assessment by a cardiac electrophysiologist; shared decision-making addressing quality of life, deactivation preferences, and device longevity (typically 7–10 years) is mandatory.
Antiarrhythmic drug therapy (amiodarone, sotalol, dofetilide) may supplement ICD therapy for arrhythmia burden reduction but does not substitute for ICD in SCD prevention.
GDMT for heart failure (ACEi/ARB/ARNI, β-blocker, MRA, SGLT2 inhibitor) must be optimised before ICD implantation, as LVEF may improve beyond 35%, potentially removing the indication.
Peri-procedural complications include pneumothorax (1–2%), lead dislodgement (2–5%), inappropriate shocks (up to 20% at 5 years), and infection (1–2%); CRT-D adds complexity and carries higher procedural risk.

Introduction & Australian Epidemiology

Sudden cardiac death (SCD) is defined as an unexpected death from a cardiac cause occurring within one hour of symptom onset (witnessed) or within 24 hours of the person being last seen alive in a normal state of health (unwitnessed). It remains one of the leading causes of mortality in Australia, responsible for an estimated 20,000–30,000 deaths per year — approximately 10–15% of all-cause mortality and roughly 50% of all cardiovascular deaths.

The epidemiology of SCD in Australia is characterised by significant inequities. Aboriginal and Torres Strait Islander peoples experience SCD at 2–3 times the rate of the non-Indigenous population, with onset at a significantly younger age (median age of SCD approximately 10 years younger than non-Indigenous Australians). Geographically, SCD rates are highest in remote and very remote areas, where access to emergency medical services, cardiac catheterisation laboratories, and electrophysiology expertise is limited.

The Australian Institute of Health and Welfare (AIHW) reports that coronary artery disease underlies approximately 75–80% of SCD cases, with the remaining attributable to non-ischaemic cardiomyopathies (10–15%), channelopathies and inherited arrhythmia syndromes (5–10%), and other structural cardiac diseases including valvular heart disease, myocarditis, and congenital heart disease. Of all out-of-hospital cardiac arrests (OHCA) attended by ambulance services across Australia (approximately 30,000 per year), fewer than 12% survive to hospital discharge, underscoring the critical importance of primary prevention strategies.

⚠️

Australian OHCA survival gap: Survival to hospital discharge from OHCA in Australia remains approximately 10–12%, with bystander CPR rates improving (now ~40–50%) but public access to AEDs still limited. ICD implantation for high-risk patients is the only proven intervention to reduce arrhythmic SCD mortality in those who have not yet arrested.

The National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (CSANZ) endorse a systematic approach to SCD risk stratification and ICD therapy aligned with international guidelines from the European Society of Cardiology (ESC, 2022) and the American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS, 2017 with 2023 focused updates). Australian practice also reflects Therapeutic Guidelines (Cardiovascular) recommendations and PBS funding arrangements that shape real-world access to device therapy.

This article provides a comprehensive clinical guideline for the prevention of SCD in Australian practice, covering risk assessment methodologies, indications for primary and secondary prevention ICD implantation, the role of the wearable cardioverter defibrillator, and considerations for special populations including Indigenous Australians.

Risk Assessment for Sudden Cardiac Death

Risk stratification for SCD is the cornerstone of prevention, guiding patient selection for ICD therapy. The approach differs fundamentally depending on whether the patient has known structural heart disease or is being evaluated for a primary electrical disease (channelopathy).

Ejection Fraction–Based Criteria

Left ventricular ejection fraction (LVEF) remains the most validated and widely used parameter for SCD risk stratification in patients with structural heart disease. The pivotal trials (MADIT, MUSTT, MADIT-II, SCD-HeFT) all used LVEF thresholds to define high-risk populations.

LVEF Threshold	Risk Category	Key Trials	ICD Recommendation
>50%	Low risk (if no other risk factors)	—	Not indicated; assess for channelopathies if appropriate
36–50%	Intermediate risk	DANISH post-hoc, MASTER trial	Consider additional risk markers (PVC burden, NSVT, CMR LGE, EPS, genetics)
≤35%	High risk	MADIT-II, SCD-HeFT, DANISH	Class I/IIa indication for primary prevention ICD (aetiology-dependent)
≤30%	Very high risk	MADIT-II subset, DINAMIT	Strong indication if >40 days post-MI and on GDMT

ℹ️

LVEF measurement: Transthoracic echocardiography using Simpson's biplane method is the standard. Cardiac MRI (CMR) with late gadolinium enhancement (LGE) provides superior reproducibility and additional prognostic information, particularly for non-ischaemic cardiomyopathy. Medicare Benefits Schedule (MBS) items 55114 (echocardiography) and 55190/55193 (CMR) are available at Australian public and private facilities.

Non-Ischaemic Dilated Cardiomyopathy

In non-ischaemic dilated cardiomyopathy (NIDCM), the relationship between LVEF and arrhythmic risk is less linear than in ischaemic cardiomyopathy. The DANISH trial (2016) demonstrated that prophylactic ICD in NIDCM reduced sudden cardiac death but did not significantly reduce all-cause mortality over a median 5.6-year follow-up, driven by competing risks of pump-failure death and improved GDMT outcomes.

Additional risk markers in NIDCM that may strengthen ICD candidacy include:

Mid-wall fibrosis on cardiac MRI (late gadolinium enhancement) — associated with 3–5-fold increased risk of arrhythmic events; this is a particularly strong discriminator in NIDCM
Non-sustained VT on Holter monitoring (≥3 consecutive beats, rate ≥120 bpm, duration <30 seconds)
Syncope of undetermined aetiology
LV end-diastolic diameter >65 mm (indexed >40 mm/m²)
Genetic testing identifying pathogenic variants in lamin A/C (LMNA), which carries particularly high arrhythmic risk and may warrant ICD even at higher LVEF (36–49%)

Channelopathies and Inherited Arrhythmia Syndromes

Patients with structurally normal hearts may still be at significant SCD risk due to inherited ion channel disorders. Risk stratification is gene-specific and phenotype-specific:

Channelopathy	Key Risk Factors	First-Line Therapy	ICD Indications
Long QT Syndrome (LQTS)	QTc >500 ms (LQT1/2/3), prior cardiac arrest, syncope on β-blockers, genotype (LQT3 highest risk)	Nadolol (LQT1/2) or propranolol; mexiletine adjunct for LQT3	Prior CA/VF, recurrent syncope on β-blockers, QTc >550 ms with high-risk features
Brugada Syndrome	Spontaneous Type 1 ECG pattern, prior syncope, male sex, SCN5A mutation, VF inducibility on EPS (controversial)	Quinidine (for VF storms); catheter ablation for recurrent VT/VF	Prior CA/VF (Class I); syncope with spontaneous Type 1 (Class IIa); asymptomatic — risk score–guided (SHFM, Appelboom)
Catecholaminergic Polymorphic VT (CPVT)	Bidirectional VT on exercise testing, RYR2/CASQ2 mutations, recurrent syncope on β-blockers	Nadolol or propranolol; flecainide adjunct	Prior CA, recurrent VT despite maximal medical therapy, high-risk genotype (RYR2 exon 3 region)

Family History and Genetic Screening

A family history of SCD (especially first-degree relatives <40 years) is an independent risk modifier. The CSANZ and Heart Foundation recommend:

Cardiac screening (12-lead ECG, echocardiography, exercise stress test) for all first-degree relatives of SCD victims, ideally through a dedicated inherited cardiac disease clinic
Genetic counselling and targeted genetic testing when a channelopathy or cardiomyopathy is suspected (MBS item 73287 for genetic consultation in select states; panel-based next-generation sequencing available at major Australian centres including Royal Melbourne, Royal Prince Alfred, Westmead, and the Victor Chang Cardiac Research Institute)
Cascade screening of family members when a pathogenic variant is identified
Comprehensive post-mortem evaluation (including genetic autopsy/molecular autopsy) for all sudden unexplained deaths, particularly in those aged 1–40 years, coordinated through state coronial services and the Australian National SUDI/SIDS Register

Electrophysiology Study and Additional Risk Markers

Invasive electrophysiology study (EPS) with programmed ventricular stimulation may be considered in selected patients (particularly ischaemic cardiomyopathy with LVEF 36–49%) to refine risk stratification. Sustained monomorphic VT inducibility predicts higher arrhythmic event rates and may strengthen ICD candidacy. Non-invasive risk markers with emerging evidence include:

Fragmented QRS on 12-lead ECG
T-wave alternans (MTWA) — negative predictive value is high but positive predictive value is modest
Heart rate variability (HRV) and heart rate turbulence
Quantification of myocardial scar burden on CMR (LGE mass, % total LV mass)
Speckle tracking echocardiography — global longitudinal strain (GLS) as a complementary parameter to LVEF

Primary Prevention ICD Therapy

Primary prevention ICD therapy is indicated for patients at high risk of SCD who have not yet experienced a life-threatening arrhythmic event. Selection requires a multi-factorial approach combining LVEF assessment, clinical status, aetiology of cardiomyopathy, and guideline-directed medical therapy (GDMT) optimisation.

⚠️

Critical timing requirement: ICD implantation for primary prevention must be deferred until ≥40 days post-MI (or ≥90 days post-revascularisation) AND ≥3 months of optimised GDMT. Premature implantation (within 40 days post-MI) was shown in DINAMIT and IRIS trials to not improve overall survival.

Ischaemic Cardiomyopathy — Primary Prevention

Ischaemic cardiomyopathy is the most common indication for primary prevention ICD worldwide. The evidence base is the most robust among all aetiologies.

Class I

Strong Indication

LVEF ≤35% measured ≥40 days post-MI (or ≥90 days post-PCI/CABG), NYHA class II or III, on optimal GDMT, expected survival >1 year with good functional status.

Evidence: MADIT-II (NNT 14 @ 3y), SCD-HeFT (NNT 14 @ 5y)

Class IIa

Reasonable

LVEF ≤30% measured ≥40 days post-MI, NYHA class I, on optimal GDMT. Also: LVEF 36–40% with inducible sustained VT/VF on EPS (per MADIT).

Evidence: MADIT-II subgroup, MUSTT

Class III — Harm

Not Indicated

Within 40 days of acute MI, within 90 days of CABG, within 90 days of PCI. NYHA class IV without CRT-D candidacy. Life expectancy <1 year. Reversible cause identified.

Evidence: DINAMIT, IRIS trials

Non-Ischaemic Dilated Cardiomyopathy — Primary Prevention

For non-ischaemic dilated cardiomyopathy, the indication for primary prevention ICD requires LVEF ≤35% despite ≥3 months of GDMT, NYHA class II–III symptoms, and expected survival >1 year. The strength of recommendation is tempered by the DANISH trial results.

ℹ️

DANISH trial implications (N Engl J Med 2016): In 1,116 patients with NIDCM, ICD reduced SCD (HR 0.50, 95% CI 0.31–0.82) but did not significantly reduce all-cause mortality (HR 0.87, 95% CI 0.68–1.12). Subgroup analyses suggested greater benefit in patients <68 years and those with non-LMNA-related cardiomyopathy. Shared decision-making is essential, incorporating patient values and comorbidity burden.

Factors strengthening ICD candidacy in NIDCM:

Mid-wall LGE on CMR (strongest independent predictor — HR ~4.5 for arrhythmic death)
LMNA pathogenic variant with ≥2 additional risk factors (non-sustained VT, LVEF <45%, male sex, missense mutation, age of onset <40)
Syncope of undetermined aetiology
Young age (<60 years) with preserved functional capacity

Hypertrophic Cardiomyopathy — Risk Stratification and ICD

HCM carries an annual SCD risk of approximately 0.5–1.0%, with higher rates in children and adolescents. The ESC 2020 guidelines recommend the HCM Risk-SCD calculator (https://www.doc2000.com/hcm) to estimate 5-year SCD risk, which integrates seven variables:

Risk Factor	Hazard Ratio	Assessment
Age at evaluation	Inverse relationship	Clinical assessment
Maximal LV wall thickness	1.04 per mm	Echocardiography or CMR
Left atrial diameter	1.06 per mm	Echocardiography
Maximal LVOT gradient at rest/Valsalva	1.01 per mmHg	Echocardiography with provocative manoeuvres
Family history of SCD	1.96	First-degree relative <40 years
Non-sustained VT on Holter	2.19	48-hour Holter monitoring (≥3 beats, ≥120 bpm)
Unexplained syncope	2.13	Clinical history; exclude vasovagal, orthostatic

✅

CMR for HCM risk assessment: Late gadolinium enhancement (LGE) on CMR is an ESC Class IIa risk modifier. LGE ≥15% of LV mass (or ≥2 g/m² indexed) is associated with significantly elevated SCD risk and may support ICD decision-making even when calculated 5-year risk is 4–6% (intermediate). MBS item 55190 funds CMR for this indication.

ICD recommendations in HCM:

Class I: Prior cardiac arrest or sustained VT; 5-year SCD risk ≥6% (HCM Risk-SCD calculator)
Class IIa: 5-year SCD risk 4–6% with additional risk factors (extensive LGE, LV apical aneurysm, LVEF <50%)
Class IIb: 5-year SCD risk <4% but ≥1 major conventional risk factor (NSVT, syncope, wall thickness ≥30 mm, family history, LA >45 mm)

Antiarrhythmic Drug Considerations

Antiarrhythmic drugs do not substitute for ICD in SCD prevention but may be used adjunctively:

💊

Amiodarone

Aratac® · Generic · Class III antiarrhythmic

Adult dose Loading: 200 mg PO TDS × 1 week → 200 mg PO BD × 1 week → maintenance 200 mg PO daily (or 100 mg daily)

Indication VT/VF burden reduction (with ICD); AF rate control; ICD shock reduction

Key adverse effects Thyroid (hypo/hyper), pulmonary fibrosis, hepatotoxicity, corneal deposits, photosensitivity, QT prolongation; requires 6-monthly TFTs, annual CXR and LFTs

Renal adjustment None required

PBS status ✔ PBS General Benefit

💊

Sotalol

Sotacor® · Generic · Class III / β-blocker

Adult dose 80–160 mg PO BD; initiate in hospital with QT monitoring; CrCl-dependent dosing

Indication VT suppression (adjunctive to ICD); AF maintenance; not a primary SCD prevention agent

Renal adjustment CrCl 30–60: 80 mg BD; CrCl 10–30: 80 mg daily; CrCl <10: avoid or 80 mg daily with monitoring

PBS status ✔ PBS General Benefit

💊

Quinidine

Quinidine bisulfate · Class IA antiarrhythmic

Adult dose Quinidine sulfate 200–400 mg PO BD–TDS (target serum level 2–5 mg/L)

Indication Brugada syndrome (VF storm prevention); LQTS type 3; NOT first-line for general VT/VF

Key adverse effects Diarrhoea, QT prolongation, cinchonism, thrombocytopenia

PBS status ✘ Not PBS listed — supplied through hospital pharmacies or Special Access Scheme

💊

Nadolol

Corgard® · Non-selective β-blocker

Adult dose 40–160 mg PO daily; titrate to resting HR 50–60 bpm

Indication First-line for LQTS (especially LQT1, LQT2); CPVT; preferred long-acting non-selective β-blocker in channelopathies

Renal adjustment CrCl 31–50: q24–36h; CrCl 10–30: q24–48h; CrCl <10: q40–60h

PBS status ✔ PBS General Benefit

GDMT Optimisation Before ICD Consideration

Before ICD implantation, GDMT for heart failure must be maximised for ≥3 months. LVEF reassessment after optimisation is mandatory, as a significant proportion of patients (25–40%) will demonstrate LVEF improvement to >35%, potentially obviating the need for a primary prevention ICD. The four pillars of GDMT are:

1

ACEi/ARB or ARNI

Sacubitril/valsartan (Entresto®) preferred over ACEi/ARB — PBS Authority Required for HFrEF. Target: sacubitril/valsartan 49/51 mg BD (or 97/103 mg BD if tolerated). Enalapril 10–20 mg BD or candesartan 32 mg daily as alternatives.

2

β-Blocker

Carvedilol (Dilatrend®) 25 mg BD (50 mg BD if >85 kg), bisoprolol (Cardicor®) 10 mg daily, or metoprolol succinate (Betaloc SA®) 200 mg daily. Only these three have mortality evidence in HFrEF.

3

Mineralocorticoid Receptor Antagonist

Spironolactone (Aldactone®) 25–50 mg daily or eplerenone (Inspra®) 25–50 mg daily. Monitor K⁺ (<5.0 mmol/L) and eGFR (>30 mL/min/1.73 m²).

4

SGLT2 Inhibitor

Dapagliflozin (Forxiga®) 10 mg daily or empagliflozin (Jardiance®) 10 mg daily — PBS listed for HFrEF regardless of diabetes status. DAPA-HF and EMPEROR-Reduced demonstrated significant reductions in HF hospitalisation and cardiovascular death.

🚨

Do not implant ICD prematurely: Implanting an ICD before GDMT optimisation risks exposing patients to device complications (inappropriate shocks, infection, psychological burden) who may improve beyond the LVEF threshold. Always reassess LVEF after ≥3 months of all four GDMT pillars before ICD decision.

Secondary Prevention ICD Therapy

Secondary prevention ICD therapy is indicated for patients who have survived a cardiac arrest or experienced sustained ventricular tachycardia (VT) in the context of structural heart disease, where the arrhythmia is not due to a completely reversible cause. The evidence base (AVID, CIDS, CASH trials) demonstrates a significant mortality reduction compared with antiarrhythmic drug therapy alone.

Indications

Class I

Cardiac Arrest Survivors

Survived cardiac arrest due to VF or pulseless VT, when a completely reversible cause has been excluded (including acute MI within 48 hours, electrolyte imbalance, drug toxicity). LVEF does not need to be ≤35% — the index event itself constitutes sufficient indication.

Evidence: AVID (NNT 10 @ 3y), CIDS, CASH meta-analysis

Class I

Sustained VT with Structural Disease

Spontaneous sustained VT (lasting ≥30 seconds or requiring intervention) in patients with structural heart disease (ischaemic or non-ischaemic cardiomyopathy), haemodynamically tolerated or not. Also: sustained VT with LVEF ≤40% even if VT is the first presentation.

Evidence: AVID, CIDS subgroup

Class IIa

Syncope with Inducible VT

Syncope of unexplained origin in patients with structural heart disease (especially ischaemic cardiomyopathy) with inducible sustained monomorphic VT on EPS. Also: unexplained syncope with LVEF ≤35% in the absence of an alternative explanation.

Evidence: MUSTT (LVEF ≤40%), expert consensus

Exclusion of Reversible Causes

Before implanting a secondary prevention ICD, a systematic evaluation for reversible or treatable causes of VT/VF must be completed:

Acute myocardial infarction (within 48 hours): VT/VF occurring in the setting of acute STEMI/NSTEMI and treated with timely revascularisation may not require ICD if LVEF recovers
Electrolyte derangement: Severe hypokalaemia (<3.0 mmol/L), hypomagnesaemia (<0.5 mmol/L), hyperkalaemia (>6.5 mmol/L)
Drug/toxin-induced: Cocaine, methamphetamine, tricyclic antidepressant overdose, antipsychotic-induced QT prolongation
Brugada pattern due to fever: Fever-induced Type 1 pattern resolving with antipyretic therapy (though cardiology follow-up is warranted)

⚠️

Timing of secondary prevention ICD: There is no mandatory waiting period for secondary prevention ICD (unlike primary prevention). Once reversible causes are excluded, ICD implantation should proceed as soon as clinically feasible. Delayed implantation increases the risk of recurrent arrhythmic events — approximately 10–30% of survivors of cardiac arrest have a recurrence within 2 years without ICD protection.

Catheter Ablation as Adjunct

Catheter ablation for VT should be considered in patients with recurrent VT episodes despite antiarrhythmic drugs, particularly in ischaemic cardiomyopathy where substrate-based ablation targeting the scar border zone has the strongest evidence (VTACH, VANISH trials). In Australia, VT ablation is available at major tertiary centres (Royal Melbourne, Royal Prince Alfred, Westmead, Flinders, Royal Adelaide, Princess Alexandra, Sir Charles Gairdner) and is MBS-reimbursed under item 38250 (catheter ablation of cardiac arrhythmia). Ablation should not delay ICD implantation in secondary prevention patients.

Post-Implantation Antiarrhythmic Drug Therapy

Many secondary prevention patients require ongoing antiarrhythmic drug therapy to reduce VT burden and ICD shocks:

Amiodarone is the most effective agent for VT suppression; reduces appropriate and inappropriate ICD shocks; requires organ monitoring (TFTs, LFTs, PFTs, ophthalmology annually)
Sotalol may be used as an alternative (class III + β-blocker effect); must be initiated in hospital with cardiac monitoring; less effective than amiodarone for VT
Mexiletine (available through Special Access Scheme in Australia) may be added to amiodarone for refractory VT
β-blockers alone are appropriate for patients with infrequent arrhythmia and ICD in situ

Wearable Cardioverter Defibrillator (WCD)

The wearable cardioverter defibrillator (WCD; LifeVest®, ZOLL Medical) is a vest-worn device that continuously monitors cardiac rhythm and delivers defibrillation therapy (typically 75–150 J biphasic) for detected VT/VF. It serves as a temporary external defibrillation bridge during clinical windows when a patient is at high SCD risk but an ICD is either contraindicated or premature.

Indications for WCD Use

1

Post-MI with LVEF ≤35% — 40-Day Window

Following acute MI with LVEF ≤35%, ICD is contraindicated within 40 days (DINAMIT, IRIS). The WCD provides arrhythmia protection during this vulnerable period while awaiting LVEF reassessment. Approximately 30–40% of patients will demonstrate LVEF improvement beyond 35% after revascularisation and GDMT, avoiding unnecessary ICD implantation.

2

GDMT Optimisation Period — Bridge to ICD Decision

Patients with newly diagnosed heart failure and LVEF ≤35% require ≥3 months of GDMT before LVEF reassessment. The WCD bridges this period, particularly when there is clinical instability, recent syncope, or non-sustained VT. WEARIT-II (registry, n=2,000) reported a 3% appropriate WCD shock rate over median 90 days of use.

3

Myocarditis Recovery Period

Acute myocarditis carries a transient period of elevated SCD risk (up to 12% in fulminant cases). ICD implantation during active inflammation is avoided due to lead-related complications and the likelihood of LV recovery. The WCD provides protection during the 3–6 month recovery window, with LVEF reassessment via CMR guiding definitive therapy.

4

Peri-Operative / Post-CABG Temporary Risk

Patients undergoing cardiac surgery with anticipated post-operative LV dysfunction may be managed with WCD during the 90-day post-revascularisation period when ICD is contraindicated per guidelines.

Practical Considerations in Australia

Availability: The WCD (LifeVest) is available in Australia through ZOLL Medical Australia. It is prescribed via specialist cardiology/electrophysiology clinics and typically funded through a combination of private health insurance, hospital funding, and patient co-payment. There is currently no dedicated PBS or MBS listing for WCD.
Wear time: Patients should aim for ≥20 hours/day of continuous wear; compliance monitoring is built into the device software and reported to the prescribing physician. Real-world adherence averages 22 hours/day in motivated patients.
Contraindications: Inability to wear the vest (severe skin disease, extreme body habitus outside available sizes), lack of cognitive capacity to respond to alarms, patients already in hospital with continuous cardiac monitoring
Alert fatigue: Non-sustained VT and artefact can trigger alarms, causing patient anxiety. Education regarding alarm management is essential. Reassurance that not all alarms indicate a life-threatening event is important.

ℹ️

WCD evidence base: The evidence for WCD is primarily from registry data (WEARIT, WEARIT-II, VEST trial for post-MI). The VEST trial (2019) randomised 2,302 post-MI patients with LVEF ≤35% to WCD vs. control and showed a non-significant 16% reduction in arrhythmic death (p=0.18) in the intention-to-treat analysis. Per-protocol analysis (accounting for adherence) showed a significant benefit. WCD use remains a Class IIa/IIb recommendation depending on the clinical scenario and guideline source.

LVEF Reassessment Pathway

After the WCD bridge period, patients must undergo systematic reassessment:

LVEF on Reassessment	Action	Rationale
Remains ≤35%	Proceed to primary prevention ICD implantation	Persistent high-risk profile; WCD bridge complete
Improved to 36–49%	Electrophysiology review; consider CMR (LGE), EPS, Holter; risk-stratify further	Intermediate risk — additional markers needed
Recovered to ≥50%	Continue GDMT; serial echo (3–6-monthly initially); ICD not indicated	Low arrhythmic risk; monitor for relapse (especially if non-ischaemic, peripartum, myocarditis)

Special Populations

🤰

Pregnancy

ICD in pregnancy Existing ICD: programming review (increase detection intervals, minimise unnecessary therapy). New implantation is feasible but fluoroscopy should be minimised — use ultrasound guidance where possible, abdominal lead shielding, lowest acceptable dose. SCD risk from underlying channelopathy (LQTS) increases peripartum — β-blockers (nadolol preferred, avoid atenolol — teratogenicity signal) should be continued throughout pregnancy.

LQTS and pregnancy LQTS type 2 carries highest risk during the post-partum period (40-fold increased risk of cardiac events). Continue nadolol/propranolol throughout pregnancy and ≥3 months post-partum. Breastfeeding is compatible with most β-blockers.

Amiodarone in pregnancy Category D (AVOID). Associated with fetal hypothyroidism, goitre, growth restriction, and prematurity. Use only for life-threatening refractory arrhythmias where no alternative exists. If used, monitor fetal thyroid function.

👶

Paediatrics

ICD implantation ICD implantation in children (<18 years) carries higher complication rates (lead fracture 15–20% at 5 years, inappropriate shocks 20–25%). Subcutaneous ICD (S-ICD) is increasingly preferred in children >25 kg to avoid transvenous lead complications. Epicardial systems for smaller children. General anaesthesia required for implantation.

Channelopathies Paediatric channelopathies (LQTS, CPVT, Brugada) require specialist inherited arrhythmia clinic management. β-blockers are first-line — nadolol preferred. CPVT: flecainide addition if breakthrough exercise-induced VT on β-blocker. Left cardiac sympathetic denervation (LCSD) is an option for refractory LQTS/CPVT.

HCM in children SCD risk is higher in paediatric HCM than adults (annual rate 1–3%). HCM Risk-SCD calculator not validated <16 years. ICD decision relies more heavily on conventional risk factors and CMR.

👴

Elderly (>75 years)

ICD benefit attenuation The absolute benefit of primary prevention ICD attenuates with age due to competing risks of non-arrhythmic death. Pooled trial data suggest NNT of 14 in patients <65 vs. 25+ in patients >75. Shared decision-making incorporating frailty assessment (clinical frailty scale), comorbidity burden, and patient preferences is paramount.

Device generator changes ICD generator replacement at 7–10 years should not be automatic in elderly patients. Deactivation should be discussed proactively, ideally by the treating electrophysiologist. Infection risk is higher in the elderly (2–3% per reintervention).

Palliative care integration Advance care planning should include discussion of ICD deactivation as part of end-of-life care. All patients with ICDs should have this conversation documented, preferably at the time of implantation. St Vincent's Health Australia and Palliative Care Australia provide frameworks for device deactivation discussions.

🫘

Chronic Kidney Disease

ICD in CKD CKD stages 4–5 and dialysis-dependent patients have higher SCD risk (5–10 fold) but also higher competing mortality from cardiovascular and non-cardiovascular causes. ICD benefit is attenuated; infection rates are 2–3× higher. Careful patient selection is required — dialysis access arm must be preserved (avoid subclavian lead placement ipsilateral to fistula).

Drug considerations Sotalol: dose adjust by CrCl (avoid if CrCl <10). Amiodarone: no renal adjustment needed but increases digoxin levels (reduce digoxin dose by 50%). Spironolactone: avoid if eGFR <30 (hyperkalaemia risk). SGLT2 inhibitors: not recommended if eGFR <20 for heart failure indication (per current PBS criteria).

🛡️

Immunocompromised

Cardiac transplant recipients Denervated hearts in transplant recipients alter arrhythmia presentation. SCD risk exists (allograft vasculopathy, rejection). ICD implantation post-transplant is uncommon but may be considered for rejection-associated VT or significant graft dysfunction.

Device infection risk Immunosuppressed patients (transplant, chemotherapy, biologics) have significantly higher ICD infection rates. Antibiotic prophylaxis is mandatory (cefazolin 2g IV pre-procedure, or vancomycin if MRSA risk). Consider subcutaneous ICD to reduce endovascular infection risk.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience disproportionately high rates of SCD, with onset at a younger age and significantly worse outcomes from out-of-hospital cardiac arrest. The AIHW reports cardiovascular disease as the leading cause of the health gap between Indigenous and non-Indigenous Australians, contributing to approximately 20% of the life expectancy gap. SCD prevention must be contextualised within a holistic health framework that acknowledges the social determinants of health, cultural safety, and the chronic under-resourcing of remote and regional cardiac services.

Higher SCD burden

Aboriginal and Torres Strait Islander peoples experience SCD at 2–3 times the rate of non-Indigenous Australians, with a median age of SCD approximately 10 years younger. Rheumatic heart disease (RHD) — rare in non-Indigenous Australia — is a significant contributor to SCD in Indigenous communities, particularly in the Northern Territory, Far North Queensland, and northern Western Australia.

Rheumatic heart disease

RHD affects Indigenous Australians at 20–60 times the rate of non-Indigenous Australians (NT data). RHD-related arrhythmias (AF, atrial flutter, VT) contribute to SCD through a combination of valvular dysfunction, left atrial enlargement, and secondary cardiomyopathy. The RHDAustralia (www.rhdaustralia.org.au) clinical guidelines recommend cardiac screening for all Aboriginal and Torres Strait Islander peoples in endemic regions.

Remote access barriers

ICD implantation and follow-up require specialist electrophysiology services concentrated in major capital cities. Patients in remote NT, WA, QLD, and SA communities face travel distances of 500–3,000 km for device implantation, and require ongoing remote monitoring (now facilitated by home monitoring systems from Medtronic, Abbott, Boston TeleCheck). The Royal Flying Doctor Service (RFDS) provides critical retrieval but cannot substitute for local specialist capacity.

Cultural safety

Cardiac device decisions must be framed within culturally safe communication, including the use of Aboriginal Health Workers (AHWs) and Aboriginal Community Controlled Health Organisations (ACCHOs) as care coordinators. Advance care planning and device deactivation discussions require particular sensitivity regarding concepts of death, Country, and family decision-making. The National Aboriginal Community Controlled Health Organisation (NACCHO) supports a holistic model of care integrating clinical, social, emotional, and cultural wellbeing.

Out-of-hospital cardiac arrest

Bystander CPR rates and public AED availability are substantially lower in remote Indigenous communities. Community-based AED deployment programs (e.g., Heart Foundation Indigenous Heart Health Program) and culturally appropriate CPR training delivered through ACCHOs are essential public health interventions. St John Ambulance Australia and the Heart Foundation have partnered on community defibrillator programs in select regions.

Young SCD and inherited conditions

Sudden unexpected death in young Aboriginal and Torres Strait Islander people (<40 years) may be under-investigated, with molecular autopsy rates lower than the non-Indigenous population. Genetic conditions (HCM, channelopathies, ARVC) are increasingly recognised. Improving post-mortem investigation pathways and family screening through regional inherited cardiac disease clinics is a priority.

📚 References

1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237. doi:10.1056/NEJMoa043399
2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883. doi:10.1056/NEJMoa013474
3. Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-1230. doi:10.1056/NEJMoa1608029
4. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576-1583. doi:10.1056/NEJM199711273372202
5. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045
6. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. doi:10.1093/eurheartj/ehac262
7. Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205-1215. doi:10.1056/NEJMoa1800781
8. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):1932-1963. doi:10.1016/j.hrthm.2013.05.014
9. Halliday BP, Gulati A, Ali A, et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135(22):2106-2115. doi:10.1161/CIRCULATIONAHA.116.026910
10. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297-1302. doi:10.1161/01.CIR.101.11.1297
11. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748-754. doi:10.1161/01.CIR.102.7.748
12. Australian Institute of Health and Welfare. Cardiovascular disease in Aboriginal and Torres Strait Islander people. AIHW; 2023. Cat. no. CVD 89.
13. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ. 2018;27(10):1123-1208. doi:10.1016/j.hlc.2018.06.1042
14. RHDAustralia (ARF/RHD writing group). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Menzies School of Health Research; 2020.
15. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-2158. doi:10.1056/NEJMoa033088
16. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481-2488. doi:10.1056/NEJMoa041489
17. Steinberg JS, Beckles MI, Socoteanu M, et al. Usefulness of the wearable cardioverter defibrillator in bridging the ICD waiting period. Circ Arrhythm Electrophysiol. 2019;12(6):e007208.
18. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21(24):2071-2078. doi:10.1053/euhj.2000.2476